On March 10, 2017 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, reported an upcoming poster presentation at the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place from April 1-5, 2017 in Washington D.C. Dr. Ana Tari Ashizawa, Director of Research at Bio-Path, will present preclinical data of BP1002 (Liposomal Bcl2 antisense), the Company’s second drug candidate, for the treatment of aggressive non-Hodgkin’s lymphoma (Filing, 8-K, Bio-Path Holdings, MAR 10, 2017, View Source [SID1234518073]). Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the poster presentation are as follows:
Date: Wednesday, April 5, 2017
Presentation Time: 8:00 am – 12:00 pm Eastern Time
Location: Walter E. Washington Convention Center
Session: Gene and Vector Based Therapy, Section 3
Abstract: 5091
Title: "Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin’s lymphoma" (Link to abstract)